The National Institute of Mental Health (NIMH) awarded a Project Grant under the Mental Health Research Grants program (CFDA 93.242) to The Feinstein Institutes for Medical Research, a non-profit medical research organization, for $1,217,886 on September 5, 2024. The goal of this 5-year project is to develop a clozapine decision support tool for first-episode psychosis (FEP) patients based on three specific biomarkers: a functional brain scan, a genetics test for weight gain risk, and a genetics...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $795,000 to the University of California, San Diego (UCSD) to conduct a multi-center, randomized clinical trial. The goal is to develop a Clozapine decision support tool using biomarkers to improve outcomes for first-episode psychosis (FEP) patients who are at risk of poor response to conventional first-line antipsychotics. The study will...
The National Institute of Mental Health (NIMH) awarded a $731,452 Project Grant under CFDA 93.242 (Mental Health Research Grants) to the University of Alabama at Birmingham (UAB) to conduct a multi-center, randomized clinical trial. The goal is to develop a decision support tool using biomarkers to guide the use of the antipsychotic medication clozapine for first-episode psychosis (FEP) patients who are at risk of poor response to first-line antipsychotics. The key biomarkers being evaluated...
This Project Grant award from the National Institute of Mental Health (NIMH), under CFDA 93.242 - Mental Health Research Grants program, provides $665,508 to the Centre for Addiction and Mental Health (CAMH) in Canada to conduct a multi-center, randomized clinical trial. The goal is to develop a clozapine decision support tool based on biomarkers to improve outcomes for first-episode psychosis patients who do not respond well to conventional first-line antipsychotics. The study will characterize...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to validate a predictive biomarker in the cerebellar-cortical circuitry for assessing treatment response to antipsychotic medication in patients with first-episode psychosis. The $519,558 award, granted on June 15, 2025, will support a 5-year research project conducted by The Feinstein Institutes for Medical Research. The key objectives are to: 1)...
This Project Grant award from the National Institute of Mental Health (CFDA 93.242 - Mental Health Research Grants) provides $2,048,026 to The Trustees of Columbia University in the City of New York to conduct research on using machine learning approaches and integrated electronic health records, dimensional phenotyping, and genetic analyses to build predictors and identify subtypes of clinical outcomes among individuals with schizophrenia. The project aims to advance precision psychiatry by...
This Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 Mental Health Research Grants provides $508,500.00 to New York University to leverage electronic health records, dimensional phenotyping, and genetic analysis to build predictive models and identify subtypes of clinical outcomes among individuals with schizophrenia. The project aims to advance precision psychiatry by developing individualized treatment planning, outcome monitoring, and preventive...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), seeks to harness collective intelligence to predict outcomes for individuals at clinical high-risk for psychosis. The $334,588 award to Beth Israel Deaconess Medical Center, Inc. (Bidmc) will fund a 2-year project to evaluate the predictive accuracy of psychiatrists and a multidisciplinary group, using clinical data and risk calculator...
This Project Grant award from the National Institute of Mental Health (CFDA 93.242 - Mental Health Research Grants) provides $1,659,568 to The Feinstein Institutes for Medical Research to conduct research aimed at improving treatment outcomes for individuals with first episode psychosis. The key products and services to be delivered include: Enrolling an additional 625 participants from 13 clinics in 6 states in the ESPRITO EPINET learning health system project, building on the current...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $1,491,482 to Brigham & Women's Hospital Inc. to investigate mechanism-based biomarkers of schizophrenia using neuroimaging. The key objectives are to utilize a novel animal model to characterize the relationship between increased extracellular water volume (free water), oxidative stress, neuroinflammation, and cognitive deficits observed in...